T-Cell Engagers (TCE’s) are one of the most promising treatment modalities for the cure of multiple, solid and hematological tumors which we earlier thought were incurable diseases. Due to the mechanism of action of these molecules, whereby, it engages T-cells towards the target cancer cells, it sometimes causes hyperinflammatory conditions releasing cytokines affecting multiple organs/organ systems. The mechanism behind the cytokine release in such conditions is known. Its diagnosis and treatment, however, is challenging and require continuous monitoring to ensure the appropriate management of this severe condition before it starts deteriorating or affecting multiple organs. Since the early diagnosis of CRS is primarily based on clinical acumen, the available CRS grading criteria drive the diagnosis and management. Although CRS grading criteria have the common objective, primarily targeted towards an immediate management of the event, consensus towards a single grading criterion might vary. My presentation will be based on a review of published literature and comprises 3 parts:
- Comparing CRS grading methodologies, observations, and features driving the conclusion. - Justification towards an early management and mitigation plan based on available CRS grading
criteria
- Discuss best practices and potential areas for further follow up/improvement to ensure optimal
patient safety.

Cytokine Release Syndrome (CRS)- Severity grading criteria and it’s management modalities

For it's 35th anniversary, DIA Europe is back in Basel, where all thought leaders meet in person to discuss, inspire, and network.

Join us in Basel: March 22-24, 2023

DIA Europe 2023 is designed to drive insights into action by connecting key policy discussions to real-world knowledge that you need for your everyday job. Your participation will accelerate your growth and your organization's performance in the drug development ecosystem.

Gathering innovative thought leaders from the entire life science landscape, DIA always has the aspiration to be ahead of current developments, reflected by 4 new content tracks in 2023:

- Artificial Intelligence and Data Science
- EU Health Policy and Regulatory Strategy
- Medical Devices and Combination Products
- Professional Development

DIA Europe 2023

A global, member-driven non-profit organization mobilizing life sciences and healthcare. DIA fosters innovation to improve health and well-being worldwide. Professionals from 80 countries continue to engage with DIA through our unparalleled membership network, educational offerings, and professional development opportunities.